

<b>NCT ID</b>	NCT05733611
<b>Title</b>	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-02-17
<b>Location</b>	
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03860272
<b>Title</b>	Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-03-01
<b>Location</b>	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Balstilimab, Botensilimab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05973487
<b>Title</b>	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-08-03
<b>Location</b>	Arizona, United States California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	

<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05217446
<b>Title</b>	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-02-01
<b>Location</b>	Arizona, United States California, United States Florida, United States Tennessee, United States Texas, United States Australia Belgium Canada Czechia Denmark France Germany Italy Netherlands Norway Poland Slovakia Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	encorafenib, Braftovi, Erbitux, Keytruda
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT04895722
<b>Title</b>	Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-05-20

<b>Location</b>	Florida, United States Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Belgium Canada Colombia Costa Rica Denmark Estonia France Germany Greece Guatemala Hungary Italy Korea, Republic of Lithuania Netherlands Poland Romania Russian Federation Spain Turkey United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT04730544
<b>Title</b>	Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-01-29
<b>Location</b>	France
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT04008030
<b>Title</b>	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
<b>Phase</b>	Phase 3
<b>Date Added</b>	2019-07-05

<b>Location</b>	California, United States
	Colorado, United States
	Illinois, United States
	New York, United States
	Oregon, United States
	Pennsylvania, United States
	Texas, United States
	Virginia, United States
	Argentina
	Australia
	Austria
	Belgium
	Brazil
	Canada
	Chile
	China
	Czechia
	Denmark
	France
	Germany
	Greece
	Ireland
	Italy
	Japan
	Netherlands
	Norway
	Puerto Rico
	Romania
	Spain
	Turkey (Türkiye)
	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin
<b>Tags</b>	MSI-H/ MMRd
<hr/>	
<b>NCT ID</b>	NCT02997228
<b>Title</b>	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
<b>Phase</b>	Phase 3
<b>Date Added</b>	2016-12-20

Location	Arizona, United States
	Arkansas, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	Delaware, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Idaho, United States
	Illinois, United States
	Indiana, United States
	Iowa, United States
	Kansas, United States
	Kentucky, United States
	Louisiana, United States
	Maine, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Mississippi, United States
	Missouri, United States
	Montana, United States
	Nebraska, United States
	Nevada, United States
	New Hampshire, United States
	New Jersey, United States
	New Mexico, United States
	New York, United States
	North Carolina, United States
	North Dakota, United States
	Ohio, United States
	Oklahoma, United States
	Oregon, United States
	Pennsylvania, United States
	South Carolina, United States
	South Dakota, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Vermont, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
	Wyoming, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, fluorouracil, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT06513221
Title	A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Phase	
Date Added	2024-07-22
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	

Drugs

Tags

MSS/ MMRp